11:17 AM
 | 
Oct 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product is a tetravalent bispecific human antibody targeting CD19 and CD3. Affimed announced the hold late Oct. 8.

AFM11 is in two Phase I trials to treat relapsed or refractory B cell non-Hodgkin lymphoma (NHL) and B cell precursor acute lymphoblastic leukemia (ALL); the...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >